Читать книгу Blood and Marrow Transplantation Long Term Management - Группа авторов - Страница 45

1 1. Aljurf M, Rizzo JD, Mohty M, et al. Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts. Bone Marrow Transplant. 2014; 49(8):1016–1021.

2 2. Horowitz M. The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008; 42(Suppl 1):S1–S2.

3 3. Bhatt NS, Brazauskas R, Tecca HR, et al. Post‐transplantation employment status of adult survivors of childhood allogeneic hematopoietic cell transplant: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Cancer. 2019; 125(1):144–152.

4 4. Eapen M, Raetz E, Zhang MJ, et al. Outcomes after HLA‐matched sibling transplantation or chemotherapy in children with B‐precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood. 2006; 107(12):4961–4967.

5 5. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem‐cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010; 11(7):653–660.

6 6. Verneris MR, Eapen M, Duerst R, et al. Reduced‐intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2010; 16(9):1237–1244.

7 7. Zhang MJ, Davies SM, Camitta BM, et al. Comparison of outcomes after HLA‐matched sibling and unrelated donor transplantation for children with high‐risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2012; 18(8):1204–1210.

8 8. Hussein AA, Hamidieh AA, Elhaddad A, et al. First report of pediatric hematopoietic stem cell transplantation activities in the eastern mediterranean region from 1984 to 2011: on behalf of the pediatric cancer working committee of the eastern mediterranean blood and marrow transplantation group. Bone Marrow Transplant. 2017; 52(1):120–125.

9 9. Iida M, Kodera Y, Dodds A, et al. Advances in hematopoietic stem cell transplantation in the Asia‐Pacific region: the second report from APBMT 2005‐2015. Bone Marrow Transplant. 2019; 54(12):1973–1986.

10 10. Paulson K, Brazauskas R, Khera N, et al. Inferior access to allogeneic transplant in disadvantaged populations: a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2019; 25(10):2086–2090.

11 11. Pavlů J, Labopin M, Niittyvuopio R, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol. 2019; 12(1):108.

12 12. Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant‐related mortality in the current era: a CIBMTR analysis. Blood. 2016; 127(20):2427–2438.

13 13. Radivoyevitch T, Dean RM, Shaw BE, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018; 74:130–136.

14 14. Gabriel M, Shaw BE, Brazauskas R, et al. Risk factors for subsequent central nervous system tumors in pediatric allogeneic hematopoietic cell transplant: a study from the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2017; 23(8):1320–1326.

15 15. Shaw BE, Hahn T, Martin PJ, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. Biol Blood Marrow Transplant. 2017; 23(1):10–23.

16 16. Chow EJ, Anderson L, Baker KS, et al. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report. Biol Blood Marrow Transplant. 2016; 22(5):782–795.

17 17. Gebauer J, Rieken S, Schuster S, et al. Multidisciplinary Late Effects Clinics for Childhood Cancer Survivors in Germany: A Two‐Center Study. Oncol Res Treat. 2018; 41(7–8):430–436.

18 18. Signorelli C, Wakefield CE, McLoone JK, et al. Models of childhood cancer survivorship care in Australia and New Zealand: Strengths and challenges. Asia Pac J Clin Oncol. 2017; 13(6):407–415.

19 19. Signorelli C, Wakefield CE, Fardell JE, et al. The impact of long‐term follow‐up care for childhood cancer survivors: A systematic review. Crit Rev Oncol Hematol. 2017; 114:131–138.

20 20. Nathan PC, Agha M, Pole JD, et al. Predictors of attendance at specialized survivor clinics in a population‐based cohort of adult survivors of childhood cancer. J Cancer Surviv. 2016; 10(4):611–618.

21 21. Groarke JM, Richmond J, Kelly MG, et al. Examining the Impact of a Personalized Self‐Management Lifestyle Program Using Mobile Technology on the Health and Well‐Being of Cancer Survivors: Protocol and Rationale for a Randomized Controlled Trial (The Moving On Study). JMIR Res Protoc. 2019; 8(8):e13214.

22 22. O'Malley DM, Davis SN, Devine KA, et al. Development and usability testing of the e‐EXCELS tool to guide cancer survivorship follow‐up care. Psychooncology. 2019; 29(1):123–131.

23 23. Quintiliani LM, Foster M, Oshry LJ. Preferences of mHealth app features for weight management among breast cancer survivors from underserved populations. Psychooncology. 2019; 28(10):2101–2104.

24 24. Zinter MS, Logan BR, Fretham C, et al. Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biol Blood Marrow Transplant. 2020; 26(2):333–342.

25 25. Herr MM, Curtis RE, Tucker MA, et al. Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. J Am Acad Dermatol. 2019;S1090–9622( 19):32952–32954.

26 26. Duncan CN, Brazauskas R, Huang J, et al. Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2018; 53(10):1278–1287.

27 27. Vrooman LM, Millard HR, Brazauskas R, et al. Survival and late effects after allogeneic hematopoietic cell transplantation for hematologic malignancy at less than three years of age. Biol Blood Marrow Transplant. 2017; 23(8):1327–1334.

28 28. Bhatt NS, Brazauskas R, Tecca HR, et al. Female sex is associated with poor health‐related quality of life in children at 12 months post‐hematopoietic cell transplantation. J Pediatr Hematol Oncol. 2019; 41(3):233–237.

29 29. D'Souza A, Millard H, Knight J, et al. Prevalence of self‐reported sleep dysfunction before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2018; 53(8):1079–1082.

30 30. Norkin M, Shaw BE, Brazauskas R, et al. Characteristics of late fatal infections after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019; 25(2):362–368.

31 31. Myers RM, Hill BT, Shaw BE, et al. Long‐term outcomes among 2‐year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b‐cell lymphoma. Cancer. 2018; 124(4):816–825.

32 32. Gratwohl A, Brand R, McGrath E, et al. Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation. Haematologica. 2014; 99(5):908–915.

33 33. Schetelig J, Wreede LC, Andersen NS, et al. Center characteristics and procedure‐related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: A retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2017; 178(4):521–533.

34 34. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007; 92(1):11–18.

35 35. Passweg JR, Baldomero H, Chabannon C, et al. The EBMT activity survey on hematopoietic‐cell transplantation and cellular therapy 2018: CAR‐T's come into focus. Bone Marrow Transplant. 2020; 55(8):1604–1613.

36 36. Snowden JA, Saccardi R, Orchard K, et al. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: a review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2020; 55(4):681–694.

37 37. Cesaro S, Pillon M, Sauer M, et al. Long‐term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman‐Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP‐EBMT). Bone Marrow Transplant. 2020; doi: 10.1038/s41409‐020‐0863‐z. [Online ahead of print].

38 38. Giardino S, de Latour RP, Aljurf M, et al. Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: a retrospective analysis on behalf of EBMT group. Am J Hematol. 202095(7):809–816.

39 39. Penack O, Peczynski C, van der Werf S, et al. Association of serum ferritin levels before start of conditioning with mortality after alloSCT: A Prospective, Non‐interventional Study of the EBMT Transplant Complications Working Party. Front Immunol. 2020; 11:586.

40 40. Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem‐cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020; 7(2):e157–e167.

41 41. Iida M, Kodera Y, Dodds A, et al. Advances in hematopoietic stem cell transplantation in the Asia‐Pacific region: the second report from APBMT 2005‐2015. Bone Marrow Transplant. 2019; 54(12):1973–1986.

42 42. Nations U. World Population Prospects 2019. 2019.

43 43. Yoshimi A, Suzuki R, Atsuta Y, et al. Hematopoietic SCT activity in Asia: a report from the Asia‐Pacific Blood and Marrow Transplantation Group. Bone Marrow Transplant. 2010; 45(12):1682–1691.

44 44. Ashton LJ, Le Marsney RE, Dodds AJ, et al. A population‐based cohort study of late mortality in adult autologous hematopoietic stem cell transplant recipients in Australia. Biol Blood Marrow Transplant. 2014; 20(7):937–945.

45 45. Atsuta Y, Hirakawa A, Nakasone H, et al. Late mortality and causes of death among long‐term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2016; 22(9):1702–1709.

46 46. Atsuta Y, Suzuki R, Yamashita T, et al. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft‐versus‐host disease. Ann Oncol. 2014; 25(2):435–441.

47 47. Gifford G, Sim J, Horne A, Ma D. Health status, late effects and long‐term survivorship of allogeneic bone marrow transplantation: a retrospective study. Intern Med J. 2014; 44(2):139–147.

48 48. Inamoto Y, Matsuda T, Tabuchi K, et al. Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation. Blood Adv. 2018; 2(15):1901–1913.

49 49. Kurosawa S, Oshima K, Yamaguchi T, et al. Quality of life after allogeneichematopoietic cell transplantation according to affected organ and severity of chronic graft‐versus‐host disease. Biol Blood Marrow Transplant. 2017; 23(10):1749–1758.

50 50. Kurosawa S, Yamaguchi T, Oshima K, et al. Employment status was highly associated with quality of life after allogeneic hematopoietic cell transplantation, and the association may differ according to patient age and graft‐versus‐host disease status: analysis of a nationwide QOL survey. Bone Marrow Transplant. 2019; 54(4):611–615.

51 51. Kurosawa S, Yamaguchi T, Oshima K, et al. Resolved versus active chronic graft‐versus‐host disease: impact on post‐transplantation quality of life. Biol Blood Marrow Transplant. 2019; 25(9):1851–1858.

52 52. Nelson AS, Vajdic CM, Ashton LJ, et al. Incident cancers and late mortality in Australian children treated by allogeneic stem cell transplantation for non‐malignant diseases. Pediatr Blood Cancer. 2017; 64(1):197–202.

53 53. Vajdic CM, Mayson E, Dodds AJ, et al. Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population‐Based Cohort Study. Biol Blood Marrow Transplant. 2016; 22(5):949–956.

54 54. Aljurf MD, Zaidi SZ, El Solh H, et al. Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report. Bone Marrow Transplant. 2009; 43(1):1–12.

55 55. Al‐Hazzouri A, Cao Q, Burns LJ, et al. Similar risks for chronic kidney disease in long‐term survivors of myeloablative and reduced‐intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008; 14(6):658–663.

56 56. Rasheed W, Ghavamzadeh A, Hamladji R, et al. Hematopoietic stem cell transplantation practice variation among centers in the Eastern Mediterranean Region (EMRO): Eastern Mediterranean Bone Marrow Transplantation (EMBMT) group survey. Hematol Oncol Stem Cell Ther. 2013; 6(1):14–19.